-
Archives
- June 2013
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- November 2010
- October 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
-
Meta
Tag Archives: mortalidad
¿A qué se debe la reducción de la mortalidad por cardiopatía isquémica?
Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW. How Much of the Recent Decline in the Incidence of Myocardial Infarction in British Men Can Be Explained by Changes in Cardiovascular Risk Factors?: Evidence From a Prospective … Continue reading
Eficacia de una intervención multifactorial sobre la diabetes para reducir la mortalidad
Eficacia de una intervención multifactorial sobre la diabetes para reducir la mortalidad Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 580-591. R … Continue reading
Posted in Articulos de interés, Diabetes Mellitus
Tagged AP al dia, Articulos de interés, Diabetes Mellitus, eficacia, mortalidad
Leave a comment
Eficacia de una intervención multifactorial sobre la diabetes para reducir la mortalidad
Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 580-591. R TC (s) PDF (s) Introducción La diabetes es un problema de … Continue reading
“Los efectos adversos de los fármacos son ya la primera causa de muerte en EE UU”
Fuente: Gonzalo Moyano en ALAMES ENTREVISTA / MIGUEL JARA, AUTOR DE ‘TRAFICANTES DE SALUD’ http://www.diagonalperiodico.net/article3044.html Belén Macías Marín . Redacción Contra el gigante blanco. El autor de Traficantes de salud, que salió a la venta la semana pasada, planta cara … Continue reading
Posted in Medicamentos
Tagged Efectos Adversos, Industria Farmaceutica, Medicamentos, mortalidad
Leave a comment
La capacidad de ejercicio es un fuerte predictor de mortalidad
La capacidad de ejercicio predice fuertemente el riesgo de muerte en hombres, de acuerdo a un estudio publicado en CirculationCerca de 16,000 hombres se sometieron a ejercicio en una banda continua y se siguieron alrededor de 7.5 años. Después del … Continue reading
Gilgamesh
Autor: Juan Gervas La economía de supervivencia empezó a convertirse en una economía de producción 10.000 años antes de Cristo, casi simultáneamente en China y en el Oriente Próximo. De la recolección se pasó lentamente a la agricultura y a … Continue reading
AP al dia: Resumenes comentados
En adultos con faringitis estreptocócicas de repetición, la amigdalectomía es eficaz para prevenir recaídas a corto plazo HTML PPT Los pacientes con síndrome del intestino irritable tienen un mayor riesgo de ser sometidos a una apendicectomía negativa HTML PPT La … Continue reading
Posted in Articulos de interés
Tagged adherencia, adultos, amigdalectomia, AP al dia, apendicectomia, Cancer, CPAP, criptocrquidia, estatinas, estreptococo, estudio REGICOR, faringitis, hipotension, infarto de miocardio, intestino irritable, mortalidad, orofaringeo, Riesgo Cardiovascular, testiculo, tratamiento, vph
Leave a comment
La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003
La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003 Susan M. Hutfless Susan M. Hutfless , ‡ , Xiaoping Weng ‡ , Liyan Liu ‡ , James Allison ‡ , § and Lisa J. … Continue reading
La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003
La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003 Susan M. Hutfless Susan M. Hutfless , ‡ , Xiaoping Weng ‡ , Liyan Liu ‡ , James Allison ‡ , § and Lisa J. … Continue reading
Physician’s First Watch
Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Fitness Strongly Predicts Mortality Risk in the Elderly, Regardless of Adiposity FDA: Desmopressin Increases Risk for Hyponatremia Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Amoxicillin or budesonide, either alone … Continue reading
Posted in First Watch
Tagged , Antibioticos, corticoides, desmopresina, ejercicio, FDA, hiponatremia, mortalidad, Physician´s First Watch, Salud en ancianos, sinusitis aguda
1 Comment
Physician's First Watch
Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Fitness Strongly Predicts Mortality Risk in the Elderly, Regardless of Adiposity FDA: Desmopressin Increases Risk for Hyponatremia Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Amoxicillin or budesonide, either alone … Continue reading
Posted in First Watch
Tagged Antibioticos, corticoides, desmopresina, ejercicio, FDA, hiponatremia, mortalidad, Physician´s First Watch, Salud en ancianos, sinusitis aguda
1 Comment
Effects of Torcetrapib in Patients at High Risk for Coronary Events
ABSTRACT Background Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because … Continue reading
Posted in Efectos Adversos, Medicamentos
Tagged , interaccion medicamentosa, Medicamentos, mortalidad, NEJM, torcetrapib
Leave a comment
Cambio en la formula del Yectafer
Las inyecciones de hierro Yectafer, utilizadas habitualmente en el tratamiento de las anemias, cambiaron su formulación, modificando uno de los componentes, según anunciaron las autoridades del laboratorio que las produce. Según señalaron en una conferencia de prensa los responsables en … Continue reading
Posted in hierro, Yectafer
Tagged , anemia, Astra Zeneca, hierro, hierro dextrano, hierro sorbitex, intramuscular, mortalidad, Noticias, opiniones, Salud materno-infantil, Yectafer
2 Comments
Leptospirosis en Republica Dominicana
INFECCIÓN RELACIONADA CON LAS LLUVIAS 26 muertos por un brote de leptospirosis en la República Dominicana Fuente: El Mundo.es Actualizado martes 20/11/2007 11:50 SANTO DOMINGO.- Al menos 26 personas murieron por un brote de leptospirosis tras el paso de la … Continue reading
Posted in Infectologia, Medio Ambiente, Noticias
Tagged , el mundo.es, leptospirosis, lluvias, Medio Ambiente, mortalidad, Noticias, republica dominicana
1 Comment
AP al dia: resumenes comentados
¿El cribado del VPH es eficaz para la prevención del cáncer de cérvix? HTML PPT Prevalencia de la enfermedad renal crónica en EEUU HTML PPT Relación entre el IMC y la causa de muerte HTML PPT Hallazgos incidentales en las … Continue reading
Posted in Uncategorized
Tagged AP al dia, Cancer, cribado, cuello uterino, enfermedad renal cronica, hallazgos en RMN, IMC, mortalidad, prevalencia, Prevencion, resumenes comentados, vph
Leave a comment
Recorriendo (un poco) la blogosfera medica
El supositorio: Breve, conciso, preciso, que más pedirle a un blog con dos posts de gran calidad. La promoción de los medicamentos en los países en vías de desarrollo Raloxifeno: incremento del riesgo de mortalidad por ictus Primum Non Nocere … Continue reading
Pediatria Basada en la Evidencia
Adolescentes y drogas. Un reto para los profesionales sanitarios Hidalgo Vicario MI, Redondo Romero A. Evid Pediatr. 2007;3:60. [HTM] [PDF] Papel protector de la lactancia materna en las infecciones de la infancia: análisis crítico de la metodología de estudio Paricio … Continue reading
Posted in Medicina Basada en la Evidencia, Salud en Adolescentes, Salud Infantil
Tagged , acido folico, Adicciones, Alcoholismo, Alimentación, autismo, broquiolitis, cancer testicular, corticoides, criptorquidia, criterios de exclusion, defectos congenitos, diagnostico por imagen, ecografia renal prenatal, edad materna, edad paterna, ensayos clinicos, estreñimiento cronico, fimosis, gastroenteritis, hipertrofia adenoidea, infeccion, infeccion osteoarticular, infeccion respiratoria, infeccion urinaria, inmunizacion, internacion, Kingella kingae, Lactancia materna, maltrato infantil, Medicina Basada en la Evidencia, mortalidad, neumococo, oximetria, paralisis cerebral infantil, peso en niños, Prevencion, pronostico, radiografia de torax, recien nacido, recien nacido de bajo peso, regulacion, salud del adolescente, Salud Infantil, serotipos, sintomas psiquiatricos, toxina botulinica, vacunacion, violencia, Virus Papiloma Humano
1 Comment
El sobrepreso disminuye la mortalidad: l@s gordit@s festejan
Hace alrededor de dos años, un equipo de científicos estatales informó que las personas con sobrepeso tienen una tasa de mortalidad más baja que las personas con peso normal, bajo peso u obesas. Ahora, después de seguir investigando, el mismo … Continue reading
Posted in mortalidad, Sobrepeso
Tagged causas de muerte, JAMA, mortalidad, peso, Sobrepeso
Leave a comment
Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial
The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading
Posted in Asma, Medicamentos, mortalidad, Salud Infantil
Tagged Asma, ensayo clinico, mortalidad, salmeterol, SMART
Leave a comment
Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial
The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading
Posted in Asma, Medicamentos, mortalidad, Salud Infantil
Tagged , Asma, ensayo clinico, mortalidad, salmeterol, SMART
Leave a comment
Journal Watch en Portugues
Diagnóstico de incontinência urinária com três perguntas Biópsia de nódulo sentinela = menos linfedema e melhor qualidade de vida (ALMANAC) Ondansentrona é efetiva para gastroenterite com vômitos Acupressão tem melhor desempenho que fisioterapia para lombalgia Ressonância não é precisa no … Continue reading
Posted in Journal Watch, WONCA
Tagged , acidos grasos, agua viva, ALMANAC, angioplastia, aspirina, biopsia, Cancer, colorectal, edema pulmonar, enfermedad arterial perfierica, enoxaparina, esclerosis multiple, estrogenos, fisioterapia, fondaparina, ganglio centinela, gastroenteritis, glitazonas, hiperhidrosis, homocisteina, incontinencia urinaria, infarto agudo de miocardio, isoflavonas, ISRS, Journal Watch, lumbalgia, mama, mamografia, morfina, mortalidad, omega 3, ondasentron, quemadura, RMN, soja, soya, tabaquismo, vacuna HPV, vomitos, WONCA
Leave a comment
AP al dia: Resumenes comentados
¿Cuáles son los principales factores relacionados con la mortalidad en mujeres? HTML PPT La incidencia de los AVC tiende a disminuir en las últimas décadas HTML PPT El consumo moderado de alcohol se asocia a una reducción del 20% de … Continue reading
GAPURMED/GAPURJovenes
